Publications by authors named "Max E Scheulen"

Claim this Profile
S
Sorafenib as first-line therapy for metastatic uveal melanoma: A multicenter, placebo-controlled randomized discontinuation study (STREAM).
Halime Kalkavan, Max E Scheulen, Eckhart Kämpgen, Ulrich Keilholz, Lucie Heinzerling

iScience· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of sorafenib induced changes in tumor perfusion of uveal melanoma metastases with dynamic contrast-enhanced ultrasound (DCE-US).
Dane Wildner, Lucie Heinzerling, Max E Scheulen, Eckhart Kaempgen, Gerold Schuler

J Cancer Res Clin Oncol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved survival in metastatic breast cancer: results from a 20-year study involving 1033 women treated at a single comprehensive cancer center.
Anja Welt, Simon Bogner, Marina Arendt, Josef Kossow, Antonia Huffziger, Max E Scheulen

J Cancer Res Clin Oncol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study.
Michael Bitzer, Marius Horger, Edoardo G Giannini, Tom M Ganten, Marcus A Wörns, Max E Scheulen

J Hepatol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors.
Klaus Mross, Heike Richly, Annette Frost, Dirk Scharr, Bahar Nokay, Max E Scheulen

Cancer Chemother Pharmacol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS).
György Bodoky, Max E Scheulen, Fernando Rivera, Jacek Jassem, Alfredo Carrato

J Gastrointest Cancer· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human phase I study of PRS-050 (Angiocal), an Anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors.
Klaus Mross, Heike Richly, Richard Fischer, Dirk Scharr, Martin Büchert, Max E Scheulen

PLoS One· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I clinical study of the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumours.
Martin R Weihrauch, Heike Richly, Michael S von Bergwelt-Baildon, Hans Jiro Becker, Manuel Schmidt, Max E Scheulen

Eur J Cancer· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.
Jeffrey R Infante, Bradley G Somer, Joon Oh Park, Chung-Pin Li, Max E Scheulen

Eur J Cancer· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioequivalence of Liposome-Entrapped Paclitaxel Easy-To-Use (LEP-ETU) formulation and paclitaxel in polyethoxylated castor oil: a randomized, two-period crossover study in patients with advanced cancer.
Marije Slingerland, Henk-Jan Guchelaar, Hilde Rosing, Max E Scheulen, Laurence J C van Warmerdam

Clin Ther· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastatic breast cancer patients.
Anja Welt, Mitra Tewes, Bahriye Aktas, Oliver O Hoffmann, Marcel Wiesweg, Max E Scheulen

Breast Cancer Res Treat· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors.
Ruth Plummer, Ayman Madi, Melinda Jeffels, Heike Richly, Bahar Nokay, Max E Scheulen

Cancer Chemother Pharmacol· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors.
Suzanne Leijen, Mark R Middleton, Patricia Tresca, Françoise Kraeber-Bodéré, Veronique Dieras, Max E Scheulen

Clin Cancer Res· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group).
Beate Schultheis, Dirk Strumberg, Lothar Bergmann, Ullrich Graeven, Axel-Rainer Hanauske, Max E Scheulen

Invest New Drugs· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses.
Jean-Luc Raoul, Jordi Bruix, Tim F Greten, Morris Sherman, Vincenzo Mazzaferro, Max E Scheulen

J Hepatol· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemosensitivity of conjunctival melanoma cell lines to single chemotherapeutic agents and combinations.
Henrike Westekemper, Michael Freistuehler, Gerasimos Anastassiou, Gordon Nareyeck, Norbert Bornfeld, Max E Scheulen

Br J Ophthalmol· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of food and a proton pump inhibitor on the pharmacokinetics of S-1 following oral administration of S-1 in patients with advanced solid tumors.
Max E Scheulen, Kaku Saito, Ralf A Hilger, Bastian Mende, Christopher Zergebel

Cancer Chemother Pharmacol· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of telatinib (BAY 57-9352): analysis of safety, pharmacokinetics, tumor efficacy, and biomarkers in patients with colorectal cancer.
Klaus Mross, Annette Frost, Max E Scheulen, Jürgen Krauss, Dirk Strumberg

Vasc Cell· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toll-like receptor 9 agonists as cancer therapeutics.
Udo Holtick, Max E Scheulen, Michael S von Bergwelt-Baildon, Martin R Weihrauch

Expert Opin Investig Drugs· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study.
Frederike Lentz, Anne Drescher, Andreas Lindauer, Magdalena Henke, Ralf A Hilger, Max E Scheulen

Anticancer Drugs· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer.
Petra Kupsch, Bernhard F Henning, Katrin Passarge, Heike Richly, Katrin Wiesemann, Max E Scheulen

Clin Colorectal Cancer· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.
Stephen Chan, Max E Scheulen, Stephen Johnston, Klaus Mross, Fatima Cardoso

J Clin Oncol· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma.
Alexander Schmittel, Max E Scheulen, Nikolaos E Bechrakis, Dirk Strumberg, Joachim Baumgart

Melanoma Res· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
Dirk Strumberg, Heike Richly, Ralf A Hilger, Norbert Schleucher, Sonke Korfee, Max E Scheulen

J Clin Oncol· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I clinical and pharmacokinetic study of BBR 3576, a novel aza-anthrapyrazole, administered i.v. every 4 weeks in patients with advanced solid tumors: a phase I study group trial of the Central European Society of Anticancer-Drug Research (CESAR).
Klaus Mross, Max E Scheulen, Thomas Licht, Clemens Unger, Heike Richly

Anticancer Drugs· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis